Vismodegib
| Evidence Level: L5 | Predicted Indications: 50 |
Quick Overview
| Item | Value |
|---|---|
| Drug Name | Vismodegib |
| DrugBank ID | DB08828 |
| Brand Names (EU) | Erivedge |
| Evidence Level | L5 |
| Predicted Indications | 50 |
| Top Prediction Score | 99.98% |
Approved Indication (EMA)
Erivedge is indicated for the treatment of adult patients with:- symptomatic metastatic basal cell carcinoma- locally advanced basal cell carcinoma inappropriate for surgery or radiotherapy
Predicted New Indications
TxGNN model predictions for potential drug repurposing:
| Rank | Indication | Score | Source |
|---|---|---|---|
| 1 | basal cell carcinoma | 99.98% | DL |
| 2 | medulloblastoma with extensive nodularity | 99.93% | DL |
| 3 | sebaceous adenocarcinoma | 99.93% | DL |
| 4 | sweat gland cancer | 99.91% | DL |
| 5 | xeroderma pigmentosum | 99.91% | DL |
| 6 | skin carcinoma | 99.88% | DL |
| 7 | annular epidermolytic ichthyosis | 99.87% | DL |
| 8 | epidermolysis bullosa simplex with mottled pigmentation | 99.86% | DL |
| 9 | prostate cancer/brain cancer susceptibility | 99.85% | DL |
| 10 | Brenner tumor | 99.83% | DL |
| 11 | cutaneous adenocystic carcinoma | 99.83% | DL |
| 12 | prostate leiomyoma | 99.83% | DL |
| 13 | skin cancer | 99.82% | DL |
| 14 | benign neoplasm of sweat gland | 99.82% | DL |
| 15 | fibroma of prostate | 99.81% | DL |
| 16 | benign reproductive system neoplasm | 99.81% | DL |
| 17 | male reproductive organ cancer | 99.81% | DL |
| 18 | trichothiodystrophy photosensitive | 99.81% | DL |
| 19 | eccrine carcinoma | 99.81% | DL |
| 20 | benign prostate phyllodes tumor | 99.79% | DL |
Showing top 20 of 50 predictions.
About TxGNN Predictions
Prediction Sources
| Source | Description |
|---|---|
| KG | Knowledge Graph - Network topology-based associations |
| DL | Deep Learning - Neural network score prediction |
Evidence Levels
| Level | Definition |
|---|---|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews |
| L2 | Single RCT or multiple Phase 2 trials |
| L3 | Observational studies / Large case series |
| L4 | Preclinical / Mechanistic / Case reports |
| L5 | AI prediction only (current) |
Clinical Validation Needed
Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.
Next Steps for Validation
- Literature Review: Search PubMed for existing evidence
- Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
- Mechanistic Analysis: Evaluate biological plausibility
- Preclinical Studies: Conduct in vitro/in vivo validation
- Clinical Trials: Design and conduct human studies
Data Access
- FHIR API:
/fhir/ClinicalUseDefinition/ - CSV Download: All Predictions
- GitHub: yao-care/EuTxGNN
Citation
If using this data, please cite:
@article{huang2023txgnn,
title={A foundation model for clinician-centered drug repurposing},
author={Huang, Kexin and others},
journal={Nature Medicine},
year={2023},
doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.